What this means
This post-marketing study is a multicenter cohort study in individuals aged 60 years or older vaccinated with Abrysvo (RSV vaccine）designed to confirm the safety in individuals aged 60 years or older under actual clinical practice in Japan.
A plain-English summary is on its way. Until then, this is the start of the registry's own summary.
- Status
- Active not recruiting
- Who can join
- Ages 60 and over
- Where
- 1 site
The science
- Registered title
- SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDER
- Trial ID
- NCT06546800 ↗
- Phase
- Not applicable
- Study type
- observational
- Conditions
- Respiratory Syncytial Virus Infection
- What is tested
- RSVpreF vaccine
- Sponsor
- Pfizer
- Ages
- 60 Years to no maximum
- Dates
- First posted Aug 9, 2024 · updated Oct 29, 2026
Registry summary
This post-marketing study is a multicenter cohort study in individuals aged 60 years or older vaccinated with Abrysvo (RSV vaccine）designed to confirm the safety in individuals aged 60 years or older under actual clinical practice in Japan.
Sites (1)
- Pfizer, Tokyo, Japan